Neutrophil to lymphocyte ratio (NLR) as a predictive marker of response to epidermal growth factor receptor (EGFR) tyrosine kinasc inhibitor (TKI) in EGFR mutation-positive non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Vaidyanathan, Gayatri [1 ]
Dy, Grace K. [1 ]
Starostik, Petr [1 ]
Dibaj, Shiva [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19117
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [2] Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
    Yun, Nicole K.
    Rouhani, Sherin J.
    Bestvina, Christine M.
    Ritz, Ethan M.
    Gilmore, Brendan A.
    Tarhoni, Imad
    Borgia, Jeffrey A.
    Batus, Marta
    Bonomi, Philip D.
    Fidler, Mary Jo
    [J]. CANCERS, 2021, 13 (06) : 1 - 15
  • [3] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    [J]. LUNG CANCER, 2019, 137 : 113 - 122
  • [4] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [5] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [6] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Epidermal Growth Factor Receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients
    Eaton, Helen
    Dutton, L.
    Wallace, A. J.
    Howard, E.
    Gaunt, L.
    Blackhall, F.
    Newman, W.
    [J]. JOURNAL OF MEDICAL GENETICS, 2011, 48 : S72 - S72
  • [8] Epidermal Growth Factor Receptor (EGFR) Mutation Testing in non-small cell lung cancer (NSCLC) patients
    Wallace, Andrew
    Howard, E.
    Dutton, L.
    Elles, R. G.
    Newman, W.
    [J]. JOURNAL OF MEDICAL GENETICS, 2010, 47 : S66 - S66
  • [9] FIRST-LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR plus ) NON-SMALL CELL LUNG CANCER (NSCLC) IN AN ISRAELI COHORT
    Ben-Arieh, S.
    Urban, D.
    Maimon, N.
    Leibowitz-Amit, R.
    Keizman, D.
    Biran, H.
    Mishaeli, M.
    Onn, A.
    Gottfried, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [10] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 83 - 84
12345